Aflibercept vs aflibercept-ayyh (Pavblu)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: June 2027 · NCT04932980 (registry estimate)
Reported efficacy
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)
Result source: NCT00509795
aflibercept-ayyh (Pavblu)
Marketed by Amgen
NCT04270747 · Phase 3 · completed
This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
Reported efficacy
Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)
Result source: NCT04270747
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Aflibercept: 7 of 7 rows · aflibercept-ayyh (Pavblu): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aflibercept Rows use multiple source trials | aflibercept-ayyh (Pavblu) |
|---|---|---|
| BCVA Gain 15 Letters responder rate · % of participants | 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4a,b,c NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wkb,c NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| CNV Area Change Mm2 absolute change · mm | -5.1 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,d,e,c,f NCT02713204 · Phase 2 · registry result, not featured evidence show 2 more doses-4.3 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence -5.3 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence | -6.276 vs -7.28 Aflibercept mm @ 52wkd,e,c,f NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| CST Change Microns absolute change · m | -46.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk4.0 mg iSONEPa,d,g,h NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses-72.4 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 12.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy | -157.1 vs -159.1 Aflibercept m @ 52wkd,g,h NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Dropout rate | 3.6%2.0mg Q4i NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results8.9%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 8.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 10.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 9.3%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 4.9%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7% NCT03022292 · Phase 4 · registry result, not featured evidence 6.1% NCT02689518 · Phase 4 · registry result, not featured evidence 11.9%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 14%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 12.9%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 15.4%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 100%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 8.7%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 12.7%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 18.2% NCT01722045 · Phase 4 · registry result, not featured evidence 6.3% NCT01950741 · Phase 4 · registry result, not featured evidence 2.2%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 0%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 8.3%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 11.3%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0.9%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 6.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 95% NCT00964795 · Phase 3 · registry result, not featured evidence 9.7%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 9.4%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 3.8% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 5%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 21.1%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 23.6%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 22.5% NCT01773954 · Phase na · registry result, not featured evidence | 5.2%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Discontinued due to AEs | 1%2.0mg Q4i NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results1.3%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.6%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.9%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.9%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.6%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence —Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence — NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 3%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 4.4%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 3.2%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 1.6%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 20%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 2.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 3.2%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 5.2% NCT01722045 · Phase 4 · registry result, not featured evidence — NCT01950741 · Phase 4 · registry result, not featured evidence —2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence —8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 1.2%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 2.4%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 2.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 3.7% NCT00964795 · Phase 3 · registry result, not featured evidence —RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination —Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 1.9% NCT04126317 · Phase 2 · registry result, not featured evidence —4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 3.2%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence — NCT01773954 · Phase na · registry result, not featured evidence | 0.3%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | 23%2.0mg Q4i NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results29.7%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 28.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.4%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.2%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 21.5%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 25.7%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 15.3%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 16.3%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 26.7%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 15.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 17.2%Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 29.2% NCT01722045 · Phase 4 · registry result, not featured evidence 2.1% NCT01950741 · Phase 4 · registry result, not featured evidence 20%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 5.7%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 13.7%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 15.6%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence 6.5%6 mg NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence 6.5%Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence —Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence 2.3%Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence 5.7%Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence 4.2%PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 32.5% NCT00964795 · Phase 3 · registry result, not featured evidence 6.9%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 7.1%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 13.2% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 10%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 15.8%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 45.9%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 5% NCT01773954 · Phase na · registry result, not featured evidence | —ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results8.1%Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.1%Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | 2.0mg Q4i vitreous floaters 16.1% nasopharyngitis 15.1% eye disorders pain 12.8% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 39 more results2.0mg Q8 nasopharyngitis 12.9% hypertension 10.9% eye disorders pain 10.2% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5mg Q4 nasopharyngitis 13.5% retinal haemorrhage 11.8% eye disorders pain 11.5% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q4 retinal haemorrhage 27.2% visual acuity reduced 14.2% hypertension 13.3% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q8 retinal haemorrhage 26.7% visual acuity reduced 19.5% macular degeneration 16.6% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5 mg Q4 retinal haemorrhage 23.6% visual acuity reduced 18.5% conjunctival haemorrhage 15.5% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 drop in visual acuity 7.7% punctate epithelial erosion 7.7% raised blood pressure 7.7% NCT03117634 · Phase 4 · registry result, not featured evidence drop in vision due to cataract 5.1% drop in visual acuity 5.1% peri-orbital oedema (extra-ocular) 2.6% NCT03117634 · Phase 4 · registry result, not featured evidence myelodysplastic syndrome 3.8% pneumonia 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence 2 mg intravitreal visual acuity reduced 15.6% conjunctival haemorrhage 14.8% nasopharyngitis 13.3% NCT02581891 · Phase 4 · registry result, not featured evidence 2 mg intravitreal conjunctival haemorrhage 13.2% nasopharyngitis 12.5% visual acuity reduced 12.5% NCT02581891 · Phase 4 · registry result, not featured evidence nasopharyngitis 21% cataract 4% conjunctival haemorrhage 3.2% NCT02305238 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.3% cataract 8.1% conjunctival haemorrhage 6.5% NCT02305238 · Phase 4 · registry result, not featured evidence hypertension 13.3% depression 6.7% ocular hypertension 6.7% NCT02120950 · Phase 4 · registry result, not featured evidence viral upper respiratory tract infection 11.2% hypertension 8.1% dry eye 6.8% NCT02120950 · Phase 4 · registry result, not featured evidence · combination viral upper respiratory tract infection 15.9% conjunctival haemorrhage 6.4% vitreous floaters 5.7% NCT02120950 · Phase 4 · registry result, not featured evidence · combination neovascular age-related macular degeneration 13% hypertension 8.4% conjunctival haemorrhage 7.8% NCT01722045 · Phase 4 · registry result, not featured evidence conjunctival hemorrhage 8.5% NCT01950741 · Phase 4 · registry result, not featured evidence 2.0 mg cataract progression 6.7% geographic atrophy progression 6.7% NCT01543568 · Phase 4 · registry result, not featured evidence 2 mg every 8 weeks cataract 11.3% subretinal fluid 8.3% nasopharyngitis 7.1% NCT02540954 · Phase 3 · registry result, not featured evidence cataract 10.2% subretinal fluid 8.4% visual acuity reduced 8.4% NCT02540954 · Phase 3 · registry result, not featured evidence 6 mg nasopharyngitis 4.7% urinary tract infection 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence urinary tract infection 5.6% nasopharyngitis 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence conjunctival haemorrhage 6% macular fibrosis 2.8% retinal pigment epitheliopathy 2.8% NCT01482910 · Phase 3 · registry result, not featured evidence macular fibrosis 11.8% visual acuity reduced 7% conjunctival haemorrhage 6.1% NCT01482910 · Phase 3 · registry result, not featured evidence visual acuity reduced 7% conjunctival haemorrhage 5.6% intraocular pressure increased 1.4% NCT01482910 · Phase 3 · registry result, not featured evidence · combination retinal haemorrhage 12.1% retinal haemorrhage 10.5% age-related macular degeneration 9.3% NCT00964795 · Phase 3 · registry result, not featured evidence eye disorders 51.7% conjunctival haemorrhage 20.7% eye irritation 6.9% NCT04200248 · Phase 2 · registry result, not featured evidence · combination eye disorders 46.4% conjunctival haemorrhage 17.9% dry eye 14.3% NCT04200248 · Phase 2 · registry result, not featured evidence · combination neovascular age-related macular degeneration fellow eye 7.5% vitreous detachment study eye 7.5% conjunctival haemorrhage fellow eye 5.7% NCT04126317 · Phase 2 · registry result, not featured evidence 4.0 mg iSONEP conjunctival haemorrhage 53.8% intraocular pressure increased 28.2% vitreous floaters 20.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.5 mg iSONEP conjunctival haemorrhage 60% activated partial thromboplastin time prolonged 12.5% vitreous floaters 12.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination conjunctival haemorrhage 34.2% retinal haemorrhage 28.9% arthralgia 7.9% NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 2mg fall 18.5% hypertension 16.6% nasopharyngitis 16.6% NCT00527423 · Phase 2 · registry result, not featured evidence 2.0 mg q12 upper respiratory tract infection 19.4% blepharitis 9.7% retinal haemorrhage 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence 2.0 mg q4 urinary tract infection 19.4% eye pain 12.9% visual acuity reduced 12.9% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q12 refraction disorder 12.5% headache 9.4% intraocular pressure increased 9.4% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q4 hypertension 18.8% bronchitis 15.6% constipation 15.6% NCT00320788 · Phase 2 · registry result, not featured evidence 4.0 mg q12 vitreous detachment 12.9% bronchitis 9.7% eye pain 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence | neovascular age-related macular degeneration 5.9% conjunctival haemorrhage 1.5% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more resultconjunctival haemorrhage 4.2% neovascular age-related macular degeneration 2.1% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: baseline_threshold differs (none recorded versus bcva<=73, bcva>=34, central_retinal_thickness>270).
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 2 versus Phase 3.
- ePopulation comparability has not been reviewed for both studies.
- fAssessment timepoints differ: 36 weeks versus 52 weeks.
- gPopulation context differs: registered conditions differ.
- hAssessment timepoints differ: 17.1 weeks versus 52 weeks.
- iPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aflibercept
show 2 more results
show 2 more results
show 2 more results
show 5 more results
show 2 more results
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 60 further endpoints in the CSV export.
aflibercept-ayyh (Pavblu)
show 8 more results
Wet Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: June 2027 · NCT04932980 (registry estimate)
Reported efficacy
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)
Result source: NCT00509795
aflibercept-ayyh (Pavblu)
Marketed by Amgen
NCT04270747 · Phase 3 · completed
This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
Reported efficacy
Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)
Result source: NCT04270747
Results for Wet Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Aflibercept: 6 of 6 rows · aflibercept-ayyh (Pavblu): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aflibercept Rows use multiple source trials | aflibercept-ayyh (Pavblu) |
|---|---|---|
| BCVA Gain 15 Letters responder rate · % of participants | 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4a,b,c NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wkb,c NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| CNV Area Change Mm2 absolute change · mm | -5.1 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,d,e,c,f NCT02713204 · Phase 2 · registry result, not featured evidence show 2 more doses-4.3 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence -5.3 vs -3.7 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence | -6.276 vs -7.28 Aflibercept mm @ 52wkd,e,c,f NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Dropout rate | 3.6%2.0mg Q4g NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results8.9%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 8.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 10.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 9.3%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 14%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 12.9%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 15.4%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 18.2% NCT01722045 · Phase 4 · registry result, not featured evidence 0%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 8.3%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 11.3%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0.9%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 95% NCT00964795 · Phase 3 · registry result, not featured evidence 9.7%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 9.4%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 3.8% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 22.5% NCT01773954 · Phase na · registry result, not featured evidence | 5.2%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Discontinued due to AEs | 1%2.0mg Q4g NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results1.3%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.6%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.9%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.9%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.6%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 3%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 4.4%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 3.2%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 1.6%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 5.2% NCT01722045 · Phase 4 · registry result, not featured evidence —8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 1.2%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 2.4%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 3.7% NCT00964795 · Phase 3 · registry result, not featured evidence —RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination —Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 1.9% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence — NCT01773954 · Phase na · registry result, not featured evidence | 0.3%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | 23%2.0mg Q4g NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results29.7%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 28.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.4%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.2%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 21.5%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 25.7%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 15.3%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 16.3%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 29.2% NCT01722045 · Phase 4 · registry result, not featured evidence 5.7%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 13.7%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 15.6%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence 6.5%6 mg NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence 6.5%Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 32.5% NCT00964795 · Phase 3 · registry result, not featured evidence 6.9%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 7.1%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 13.2% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 5% NCT01773954 · Phase na · registry result, not featured evidence | —ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results8.1%Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.1%Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | 2.0mg Q4g vitreous floaters 16.1% nasopharyngitis 15.1% eye disorders pain 12.8% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 24 more results2.0mg Q8 nasopharyngitis 12.9% hypertension 10.9% eye disorders pain 10.2% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5mg Q4 nasopharyngitis 13.5% retinal haemorrhage 11.8% eye disorders pain 11.5% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q4 retinal haemorrhage 27.2% visual acuity reduced 14.2% hypertension 13.3% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q8 retinal haemorrhage 26.7% visual acuity reduced 19.5% macular degeneration 16.6% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5 mg Q4 retinal haemorrhage 23.6% visual acuity reduced 18.5% conjunctival haemorrhage 15.5% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg intravitreal visual acuity reduced 15.6% conjunctival haemorrhage 14.8% nasopharyngitis 13.3% NCT02581891 · Phase 4 · registry result, not featured evidence 2 mg intravitreal conjunctival haemorrhage 13.2% nasopharyngitis 12.5% visual acuity reduced 12.5% NCT02581891 · Phase 4 · registry result, not featured evidence nasopharyngitis 21% cataract 4% conjunctival haemorrhage 3.2% NCT02305238 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.3% cataract 8.1% conjunctival haemorrhage 6.5% NCT02305238 · Phase 4 · registry result, not featured evidence neovascular age-related macular degeneration 13% hypertension 8.4% conjunctival haemorrhage 7.8% NCT01722045 · Phase 4 · registry result, not featured evidence 2 mg every 8 weeks cataract 11.3% subretinal fluid 8.3% nasopharyngitis 7.1% NCT02540954 · Phase 3 · registry result, not featured evidence cataract 10.2% subretinal fluid 8.4% visual acuity reduced 8.4% NCT02540954 · Phase 3 · registry result, not featured evidence 6 mg nasopharyngitis 4.7% urinary tract infection 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence urinary tract infection 5.6% nasopharyngitis 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence retinal haemorrhage 12.1% retinal haemorrhage 10.5% age-related macular degeneration 9.3% NCT00964795 · Phase 3 · registry result, not featured evidence eye disorders 51.7% conjunctival haemorrhage 20.7% eye irritation 6.9% NCT04200248 · Phase 2 · registry result, not featured evidence · combination eye disorders 46.4% conjunctival haemorrhage 17.9% dry eye 14.3% NCT04200248 · Phase 2 · registry result, not featured evidence · combination neovascular age-related macular degeneration fellow eye 7.5% vitreous detachment study eye 7.5% conjunctival haemorrhage fellow eye 5.7% NCT04126317 · Phase 2 · registry result, not featured evidence 2.0 mg q12 upper respiratory tract infection 19.4% blepharitis 9.7% retinal haemorrhage 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence 2.0 mg q4 urinary tract infection 19.4% eye pain 12.9% visual acuity reduced 12.9% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q12 refraction disorder 12.5% headache 9.4% intraocular pressure increased 9.4% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q4 hypertension 18.8% bronchitis 15.6% constipation 15.6% NCT00320788 · Phase 2 · registry result, not featured evidence 4.0 mg q12 vitreous detachment 12.9% bronchitis 9.7% eye pain 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence | neovascular age-related macular degeneration 5.9% conjunctival haemorrhage 1.5% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more resultconjunctival haemorrhage 4.2% neovascular age-related macular degeneration 2.1% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: baseline_threshold differs (none recorded versus bcva<=73, bcva>=34, central_retinal_thickness>270).
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 2 versus Phase 3.
- ePopulation comparability has not been reviewed for both studies.
- fAssessment timepoints differ: 36 weeks versus 52 weeks.
- gPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aflibercept
show 2 more results
show 2 more results
show 2 more results
show 5 more results
show 2 more results
show 6 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 12 more results
show 2 more results
+ 36 further endpoints in the CSV export.
aflibercept-ayyh (Pavblu)
show 8 more results
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · aflibercept-ayyh (Pavblu)'s landscape